Posted by Michael Wonder on 05 Oct 2018
FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old
5 October 2018 - The U.S. FDA today approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) expanding the approved use of the vaccine to include women and men aged 27 through 45 years.
Gardasil 9 prevents certain cancers and diseases caused by the nine HPV types covered by the vaccine.
The FDA granted the Gardasil 9 application priority review status. This program facilitates and expedites the review of medical products that address a serious or life-threatening condition.
